This Consulting Agreement (the “Agreement”) is entered into as of May 1, 2008 by and between Perrigo
Company, 515 Eastern Avenue, Allegan, MI (together with its affiliates, “Perrigo”), and Moshe Arkin, 22
Derech Haganim, Kefar-Shmaryaho, Israel and M. Arkin Ltd. collectively referred to as (“Arkin”).
WHEREAS Perrigo desires to retain Arkin to provide advice and consultation concerning Perrigo’s generic
prescription and API product selection and R&D efforts (the “Project”), and Arkin is willing to be retained by
Perrigo relative to the Project and to perform all consulting services on a “best efforts” basis.
WHEREAS Perrigo and Arkin desire to make this Agreement relative to the Project effective as of March 18,
2008 (the “Effective Date”).
NOW, THEREFORE, Perrigo and Arkin agree as follows:
1 SCOPE OF ARRANGEMENT
1.1 Perrigo engages Arkin, and Arkin accepts such engagement, to provide advice and consultation to
Perrigo regarding the Project.
1.2 During the Term (as defined below) of this Agreement, Arkin agrees to perform the following services
relative to the Project:
Chair Perrigo’s Product Selection Committee for the generic prescription drug business and
provide advice, consultation and direction relative to product selection for the Rx and API
provide advice and consultation concerning Perrigo’s R&D efforts relative to the Generic Rx,
API and Israeli – Pharma businesses;
provide advice and consultation relative to Perrigo’s strategic initiatives; and
perform any other task or assignment as may be required or needed relative to the Project.
2 COMPENSATION AND ACCOUNTING
2.1 During the Term, Perrigo agrees to pay Arkin, as full and complete consideration for his advisory and
consultation services relative to the Project, an annual fee of $370,000 USD, payable in substantially
equal monthly installments. In addition, Perrigo will reimburse Arkin for his reasonable and